Tango Therapeutics (TNGX) Depreciation & Amortization (CF) (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Depreciation & Amortization (CF) of $500000.0 for Q1 2026, down 16.67% year-over-year from $600000.0 in Q1 2025, and up 4.38% quarter-over-quarter from $479000.0 in Q4 2025.
Tango Therapeutics (TNGX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Tango Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $500000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 16.67% year-over-year to $500000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 12.76% YoY), while the FY2025 annual figure was $2.3 million, down 8.76% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $500000.0, up from $479000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $657000.0 in Q2 2024, with the low at $300000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $600000.0 (2023), against an average of $547294.1.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 120.08% in 2022, then slipped 20.17% in 2025.
- Tango Therapeutics' Depreciation & Amortization (CF) stood at $570000.0 in 2022, then grew by 8.25% to $617000.0 in 2023, then decreased by 2.76% to $600000.0 in 2024, then retreated by 20.17% to $479000.0 in 2025, then climbed by 4.38% to $500000.0 in 2026.
- Business Quant data shows TNGX's Depreciation & Amortization (CF) at $500000.0 in Q1 2026, $479000.0 in Q4 2025, and $602000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 479,000.00 |
| Dec 31, 2025 | 479,000.00 |
| Sep 30, 2025 | 602,000.00 |
| Sep 30, 2025 | 602,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 643,000.00 |
| Sep 30, 2024 | 643,000.00 |
| Jun 30, 2024 | 657,000.00 |
| Jun 30, 2024 | 657,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Mar 31, 2024 | 600,000.00 |